-
1
-
-
34249999500
-
Adjuvant mitotane treatment for adrenocortical carcinoma
-
Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356:2372-80.
-
(2007)
N Engl J Med
, vol.356
, pp. 2372-2380
-
-
Terzolo, M.1
Angeli, A.2
Fassnacht, M.3
-
2
-
-
0033788018
-
Clinical results of the use of mitotane for adrenocortical carcinoma
-
Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 2000;33:1191-6.
-
(2000)
Braz J Med Biol Res
, vol.33
, pp. 1191-1196
-
-
Kasperlik-Zaluska, A.A.1
-
3
-
-
0031741686
-
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
-
Dickstein G, Shechner C, Arad E, Best L-A, Nativ O. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-3.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 3100-3103
-
-
Dickstein, G.1
Shechner, C.2
Arad, E.3
Best, L.-A.4
Nativ, O.5
-
4
-
-
0033331698
-
Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
-
Barzon L, Fallo F, Sonino N, Daniele O, Boscaro M. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1999;84:1488-9.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, pp. 1488-1489
-
-
Barzon, L.1
Fallo, F.2
Sonino, N.3
Daniele, O.4
Boscaro, M.5
-
5
-
-
0027190328
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer
-
Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-23.
-
(1993)
Cancer
, vol.71
, pp. 3119-3123
-
-
Vassilopoulou-Sellin, R.1
Guinee, V.F.2
Klein, M.J.3
-
6
-
-
0033784724
-
Conventional and novel strategies in the treatment of adrenocortical cancer
-
Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 2000;33:1197-200.
-
(2000)
Braz J Med Biol Res
, vol.33
, pp. 1197-1200
-
-
Schteingart, D.E.1
-
7
-
-
0017610321
-
The in-vitro metabolism of 1-(o-chlorophenyl)-1-(p- chlorophenyl)-2,2-dichloroethane (o,p′-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: A possible mechanism for the adrenocorticolytic effect
-
Martz F, Straw JA. The in-vitro metabolism of 1-(o-chlorophenyl)-1-(p- chlorophenyl)-2,2-dichloroethane (o,p′-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect. Drug Metab Dispos 1977;5:482-6.
-
(1977)
Drug Metab Dispos
, vol.5
, pp. 482-486
-
-
Martz, F.1
Straw, J.A.2
-
9
-
-
17644399691
-
-
Schteingart DE, Doherty GM, Gauger et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005;12:667-80.
-
Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005;12:667-80.
-
-
-
|